Income Tax Disclosure [Abstract] Valuation allowance, increase amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Federal net operating loss carryforwards Operating Loss Carryforwards Deferred tax assets, alternative minimum tax Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax Operating loss carryforwards from excess tax deduction on stock option activity Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Unrecognized tax benefits Unrecognized Tax Benefits Accounting Policies [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Cash Equivalents Cash, Cash Equivalents, and Short-term Investments [Text Block] Restricted Cash and Cash Equivalents Restricted Cash and Cash Equivalents [Policy Text Block] Restricted Cash and Cash Equivalents [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounts Receivable Trade and Other Accounts Receivable, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Warrant Liability Derivatives, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Research and Development Research and Development Expense, Policy [Policy Text Block] Goodwill Goodwill, Policy [Policy Text Block] Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill. Share-based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Legal Contingencies Commitments and Contingencies, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Payables and Accruals [Abstract] Bonus Accrued Bonuses, Current Professional fees Accrued Professional Fees, Current Vacation Accrued Vacation, Current Other (primarily R&D vendors and CMOs) Other Accrued Liabilities, Current Accrued expenses and other current liabilities Accrued Liabilities, Current Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Options Employee Stock Option [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of shares outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of shares exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Number of shares canceled and expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Number of shares outstanding at end of period Number of shares vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Number of shares exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted average exercise price outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise price, granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price, exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price, canceled and expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted average exercise price outstanding at end of period Weighted average exercise price, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted average exercise price, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining life, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining life, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining life, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Intrinsic value, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Intrinsic value, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Equity [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash and cash equivalents-short term Restricted Cash and Cash Equivalents, Current Accounts receivable Accounts Receivable, Net, Current Inventory Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Restricted cash and cash equivalents-long term Restricted Cash and Cash Equivalents, Noncurrent Deferred costs Deferred Costs, Noncurrent Goodwill Goodwill Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] Accounts payable Accounts Payable, Current Accrued expenses and other current liabilities Warrant liability Warrants and Rights Outstanding Total current liabilities Liabilities, Current Deferred revenue Deferred Revenue, Noncurrent Deferred income tax liability, net Deferred Tax Liabilities, Net, Noncurrent Other liabilities Other Liabilities Liabilities subject to compromise Liabilities Subject to Compromise Loan payable Loans Payable Total liabilities Liabilities Stockholders’ deficit Stockholders' Equity Attributable to Parent [Abstract] Common stock ($.0001 par value, 600,000,000 shares authorized, 78,692,612 and 54,114,296 issued and outstanding at December 31, 2016, and December 31, 2015, respectively) Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ deficit Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ deficit Liabilities and Equity Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Income Statement [Abstract] Revenues Revenues [Abstract] Research and development Research and Development Revenue Revenue earned during the period arising from services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts and any other contract related to a particular project or product. Operating expenses Operating Expenses [Abstract] Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Patent preparation fees Patent Preparation Fees The aggregate costs incurred for fees associated with the protection and expansion of patents and related intellectual property. Litigation accrual expense Loss Contingency, Loss in Period Interest on PharmAthene liability Litigation Settlement Interest Total operating expenses Operating Expenses Operating loss Operating Income (Loss) Decrease (increase) in fair value warrant liability Increase In Fair Value Of Warrants Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock. Interest expense Interest Expense Backstop fee - see Note 8 Backstop Fee Backstop Fee Other income, net Nonoperating Income (Expense) Reorganization items, net Reorganization Items Loss before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Net and comprehensive loss Net Income (Loss) Attributable to Parent Earnings (loss) per share: basic and diluted (usd per share) Earnings Per Share, Basic and Diluted Weighted average shares outstanding: basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Lab equipment Lab equipment [Member] Long lived, depreciable assets that are used in the laboratory. Computer Equipment Computer Equipment [Member] Furniture and Fixtures Furniture and Fixtures [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Receivables percentage Receivables Percentage Percentage of accounts receivables represented from National Institutes of Health and BARDA. Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Property, Plant and Equipment [Abstract] Property, plant and equipment Property, Plant and Equipment [Table Text Block] Income Taxes Income Tax Disclosure [Text Block] Balance Sheet Parenthetical [Abstract] Balance Sheet Parenthetical [Abstract] Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Significant Accounting Policies Significant Accounting Policies [Text Block] Accrued Expenses Accrued expenses and other current liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. 2017 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2018 Operating Leases, Future Minimum Payments, Due in Two Years 2019 Operating Leases, Future Minimum Payments, Due in Three Years 2020 Operating Leases, Future Minimum Payments, Due in Four Years Total Operating Leases, Future Minimum Payments Due Quarterly Financial Information [Abstract] Unaudited Quarterly Results [Abstract] Selling, general and administrative expense Research and development expense Operating loss Net income (loss) Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Reorganization [Abstract] Reorganization [Abstract] Legal fees Debtor Reorganization Items, Legal and Advisory Professional Fees Professional fees Reorganization, Professional Fees Amount of reorganization items related to professional fees related to entities in bankruptcy. Trustee fees Reorganization, Trustee fees Amount of reorganization items for trustee fees related to entities in bankruptcy. Other Debtor Reorganization Items, Other Expense (Income) Total Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Number of shares outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Number of shares vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Number of shares canceled and expired Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of shares outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted average grant-date fair value outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average grant-date fair value, granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant-date fair value, vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted averaged grant-date fair value, canceled and expired Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted average grant-date fair value outstanding at end of period Organization and Basis of Presentation [Abstract] Organization and Basis of Presentation [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast Scenario, Forecast [Member] Debt Instrument Capacity by Specific Purpose [Axis] Debt Instrument Capacity by Specific Purpose [Axis] Debt Instrument Capacity by Specific Purpose [Axis] Debt Instrument Capacity by Specific Purpose [Domain] Debt Instrument Capacity by Specific Purpose [Domain] [Domain] for Debt Instrument Capacity by Specific Purpose [Axis] Repayment of Interests Repayment of Interests [Member] Repayment of Interests [Member] Payments Related to Litigation Payments Related to Litigation [Member] Payments Related to Litigation [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Loan Agreement Loan Agreement [Member] Loan Agreement [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Secured Debt Secured Debt [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Line of credit facility Line of Credit Facility, Maximum Borrowing Capacity Margin for term loan Debt Instrument, Basis Spread on Variable Rate Capacity available for specific purpose other than for trade purchases Line of Credit Facility, Capacity Available for Specific Purpose Other than for Trade Purchases Additional borrowing capacity Line of Credit Facility, Additional Borrowing Capacity Line of Credit Facility, Additional Borrowing Capacity Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Subscription Right Subscription Right [Member] Subscription Right [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Warrants Warrant [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Warrants purchased, value Class of Warrant or Right, Number of Securities Called by Warrants or Rights Exercise price of warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Exercisable period for warrants (in years) Class of Warrant or Right, Period from which Warrants or Rights are Exercisable Class of Warrant or Right, Period from which Warrants or Rights are Exercisable Warrants that can be purchased, shares Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Fair value of warrant Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Private Placement Private Placement [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Common Stock [Member] Equity Rights Equity Rights [Member] Equity Rights [Member] Capital units, authorized Capital Units, Authorized Preferred stock, shares authorized Preferred Stock, Shares Authorized Equity offering Proceeds from Issuance of Warrants Issuance of common stock associated with rights offering, shares Stock Issued During Period, Shares, Rights Offering Stock Issued During Period, Shares, Rights Offering Amount to be invested by each right to purchase securities (in dollars per share) Class of Warrant or Right, Amount to be Invested by Each Warrant or Right to Purchase Securities, Per Share Class of Warrant or Right, Amount to be Invested by Each Warrant or Right to Purchase Securities, Per Share Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Volume of weighted average price during market hours (as a percent) Class of Warrant or Right, Exercise Price of Warrants or Rights, Volume of Weighted Average Price During Market Hours, Percentage Class of Warrant or Right, Exercise Price of Warrants or Rights, Volume of Weighted Average Price During Market Hours, Percentage Share price Share Price Backstop fee Payments of Stock Issuance Costs Risk free interest rate (as a percent) Fair Value Assumptions, Risk Free Interest Rate Expected dividend rate (as a percent) Fair Value Assumptions, Expected Dividend Rate Expected term (in years) Fair Value Assumptions, Expected Term Expected volatility rate (as a percent) Fair Value Assumptions, Expected Volatility Rate Increase in fair value of warrant liability Liabilities Subject to Compromise [Abstract] Liabilies subject to compromise Liabilies subject to compromise [Table Text Block] [Table Text Block] for Schedule of liabilities that are subject to compromise. Reorganization items Reorganization items [Table Text Block] The schedule represents a summary of reorganization items. Deferred income tax assets: Components of Deferred Tax Assets [Abstract] Net operating losses Deferred Tax Assets, Operating Loss Carryforwards Deferred research and development costs Deferred Tax Assets, Tax Deferred Expense Amortization of intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Fixed assets Deferred Tax Assets, Property, Plant and Equipment Deferred revenue Deferred Tax Assets, Deferred Income Alternative minimum tax credits Loss contingency Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Other Deferred Tax Assets, Other Deferred income tax assets Deferred Tax Assets, Gross Deferred income tax assets, net of valuation allowance Deferred Tax Assets, Valuation Allowance Deferred income tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Deferred income tax liabilities: Components of Deferred Tax Liabilities [Abstract] Amortization of goodwill Deferred Tax Liabilities, Goodwill Capitalized contract costs Deferred Tax Liabilities, Capitalized Contract Costs Amount of deferred tax liability attributable to taxable temporary differences from capitalized contract costs. Other Deferred Tax Liabilities, Other Deferred income tax liability, net Deferred Tax Liabilities, Net Leasehold improvements, gross Leasehold Improvements, Gross Computer equipment, gross Computer Equipment The gross amount of capitalized computer equipment costs as of the balance sheet date. Furniture and fixtures, gross Furniture and Fixtures, Gross Property, plant and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation, depletion and amortization, property, plant, and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Inventory Disclosure [Abstract] Work in process Inventory, Work in Process and Raw Materials Finished goods Inventory, Finished Goods, Net of Reserves Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Public Float Entity Public Float Financial Information By Quarter Quarterly Financial Information [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Secured Term Loan Senior Secured Term Loan [Member] Senior Secured Term Loan [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Loan outstanding Long-term Debt Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Current federal tax expense (benefit) Current Federal Tax Expense (Benefit) Current state and local tax expense (benefit) Current State and Local Tax Expense (Benefit) Current income tax expense (benefit) Current Income Tax Expense (Benefit) Deferred federal income tax expense (benefit) Deferred Federal Income Tax Expense (Benefit) Deferred state and local income tax expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred income tax expense (benefit) Deferred Income Tax Expense (Benefit) Benefit from (provision for) income taxes Inventory write-downs Inventory Write-downs Inventory write-downs included in research and development expense on the balance sheet. Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Number of shares exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period The number of exercises made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Number of shares exercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other then Options, Exercisable Number The number of shares into which fully or partially vested, other than stock (or unit) option plans outstanding as of the balance sheet date can be currently converted under the option plan. Weighted average exercise price outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price The weighted-average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Weighted average exercise price granted Share-based Compensation Arrangement by Share-based Payment Award, Options Granted, Weighted Average Excercise Price The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of granted options under the stock option plan. Weighted average exercise price exercised Share-based Compensation Arrangement by Share-based Payment Award, Options Excercised, Weighted Average Excercise Price The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of exercised options under the stock option plan. Weighted average exercise price canceled and expired Share-based Compensation Arrangement by Share-based Payment Award, Options Canceled / Expired, Weighted Average Excercise Price The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of canceled and expired options under the stock option plan. Weighted average exercise price outstanding at end of period Weighted average exercise price, vested and expected to vest Share-based Compensation Arragement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Weighted Average Excercise Price As of the balance sheet date, the weighted average excercise price for outstanding equity instruments other than options that are fully vested of expected to vest. Weighted average exercise price, exercisable Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Weighted average remaining life, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Weighted Average Remaining Life The weighted-average remaining life in years, for equity instruments other than options vested and expected to vest. Weighted average remaining life, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Remaining Life The weighted-average remaining life in years, for excercisable equity instruments other than options. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Intrinsic value outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Intrinsic Value Amount of difference between fair value of the underlying equity instruments reserved for issuance and exercise price of equity instruments outstanding. Intrinsic value, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share Intrinsic value, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Intrinsic Value Amount of difference between fair value of the underlying equity instrument for the issuance and exercise price of vested portions of equity instruments outstanding and currently exercisable. Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of quarterly financial information Schedule of Quarterly Financial Information [Table Text Block] Amount paid to settle claims Bankruptcy Claims, Amount Paid to Settle Claims Amount to be paid on effective date of plan of reorganization Amount To Be Paid On Effective Date of Plan Of Reorganization The amount the Company is to pay PharmAthene on the effective date of the plan of reorganization. Payment to extend 120 days to satisfy pharmAthene claim payment to extend 120 days to satisfy pharmAthene claim payment to extend 120 days to satisfy pharmAthene claim Payment to extend days to satisfy claim Payment To Extend Days To Satisfy Claim Total amount of payment to PharmAthene to extend the number of days to satisfy the claim. Payments for legal settlements Payments for Legal Settlements Inventory Inventory Disclosure [Text Block] Depreciation and other amortization Depreciation, Depletion and Amortization Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity Affiliated Entity [Member] Member of Board of Directors Management [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Free rent period Free Rent Period Free Rent Period in months allowed under the sublease. Monthly rental payments first five years Monthly Rental Payments First Five Years The amount of the monthly rental payments due under the sublease entered into for the first five years. Initial rent period Initial Rent Period Represents the number of years for the initial rent period of five years and related monthly payments. Monthly rental payments after five years Monthly Rental Payments After Five Years The amount of the monthly rental payments due under the sublease entered into after the first five years. Rent period after first five years Rent Period After First Five Years Represents the amount of years after the initial rent period of first five years of which monthly rental payments will increase. Legal fees Legal Fees Accounts payable to related party Accounts Payable, Related Parties Range [Axis] Range [Axis] Range [Domain] Range [Domain] Maximum Maximum [Member] Minimum Minimum [Member] Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Stock-based compensation expense Allocated Share-based Compensation Expense Unrecognized stock-based compensation cost, net of estimated forfeitures Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted average remaining requisite service period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Fair value of vested stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Total intrinsic value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Performance-based stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Performance Based, Number The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date subject to performance conditions under the option plan. Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Maximum number of shares to be issued Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares that Could Be Issued Share-based compensation arrangement by share-based payment award, maximum number of shares that could be issued Fair value of vested stock appreciation rights Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Unrecognized stock-based compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Fair value of stock compensation vested Stock Issued During Period, Value, Restricted Stock Award, Gross Warrant liability at September 02, 2016 - issuance date Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Increase in fair value of warrant liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Warrant liability at December 31, 2016 Number of subscription rights called by each equity right Related Party Transactions Related Party Transactions Disclosure [Text Block] Procurement Contract [Table] Procurement Contract [Table] Procurement Contract [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Procurement Contract [Axis] Procurement Contract [Axis] Procurement Contract [Axis] Procurement Contract [Domain] Procurement Contract [Domain] Procurement Contract [Domain] BARDA Contract Barda Contract [Member] Barda Contract [Member] Procurement Contract [Line Items] Procurement Contract [Line Items] Procurement Contract [Line Items] Proceeds from manufacture and physical delivery of course, government contractses Proceeds From Manufacture And Physical Delivery Of Courses, Government Contracts Proceeds from manufacture and physical delivery of courses, government contracts. Government contract, total number of courses required to be delivered Government Contract, Total Number of Courses Required to Be Delivered Government Contract, Total Number of Courses Required to Be Delivered Reduced holdback amount Reduced holdback amount Reduced holdback be received from BARDA Research and Development [Abstract] Procurement Contract and Research Agreements Procurement Contract and Research Agreements [Text Block] The entire disclosure for procurement contracts and research agreements including grants or contracts from various agencies of the U.S. government to support the reporting entity's research and development activities. Inventory Schedule of Inventory, Current [Table Text Block] Revenue, percentage Revenue Percentage Percentage of revenue represented from National Institutes of Health and BARDA. Schedule of components of income tax expense (benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of effective income tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Accrued Expenses Accrued expenses and other current liabilities [Text Block] The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period. Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case Type [Domain] Litigation Case [Domain] License Agreement litigation License Agreement Litigation [Member] License Agreement Litigation [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Settled Litigation Settled Litigation [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Rent reduction Rent Reduction The amount of reduced monthly rent for the research and development facility due to the addendum to the Commercial Lease. Rent expense Rent expense Facilities Lease Rental expense incurred for facilities leased. Number of courses to be delivered Number of Courses To Be Delivered 1 Number of tecovirimat, also known as ST-246, courses to be delivered to the U.S. Strategic National Stockpile Final order and judgment Final Order And Judgment Final order and judgment entered by the Court awarding damages to the Plaintiff. Final order and judgment post-judgment interest Final Order And Judgment Post-Judgment Interest Final order and judgment post-judgment interest entered by the Court awarding damages to the Plaintiff. Final order and judgment including interest Final order and judgment plus interest Final Order and Judgment entered by the Court awarding expectation damages, plus pre-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Statement of Cash Flows [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation Share-based Compensation Gain on sale of assets Gain (Loss) on Disposition of Assets Non-cash backstop fee Stock Issuance Fees Expense Stock Issuance Fees Expense Loss on disposal of assets Loss On Disposal Of Assets Amount of loss on disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. Non-cash interest expense Other Noncash Expense Interest expense on term loan - paid with restricted cash Payment of Interest Expense Payment of Interest Expense Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Deferred costs Increase (Decrease) in Deferred Charges Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Other assets Increase (Decrease) in Other Operating Assets Deferred income taxes, net Accounts payable, accrued expenses and other current liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Liabilities subject to compromise Liabilities Subject to Compromise, Period Increase (Decrease) Deferred revenue Increase (Decrease) in Deferred Revenue Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Proceeds from sale of assets Proceeds from Sale of Productive Assets Return of collateral for surety bond Collateral for Surety Bond Collateral for Surety Bond Restricted cash Payments for (Proceeds from) Other Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net proceeds from exercise of warrants and options Proceeds From Issuance Of Warrants and Options The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Net proceeds from equity rights offering - net of offering costs Proceeds from Equity Rights Offering, Net Proceeds from Equity Rights Offering, Net Payment of employee tax obligations for common stock tendered Payments Related to Tax Withholding for Share-based Compensation Debt issuance costs Payments of Debt Issuance Costs Repayment of long-term debt Repayments of Long-term Debt Excess tax benefit from stock-based compensation Change In Excess Tax Benefit Stock-Based Compensation, Financing Activities Amount of cash inflow/(outflow) from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes. Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease) increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosures of cash flows information: Supplemental Cash Flow Information [Abstract] Portion of Term Loan paid directly to PharmAthene by the Lender in satisfaction of the PharmAthene claim; such liability is part of the Liabilities Subject to Compromise line item Notes Reduction Cash interest paid on PharmAthene liability Interest Paid on PharmAthene Liability Interest Paid on PharmAthene Liability Cash interest paid on Term Loan from restricted cash Interest Paid on Term Loan From Restricted Cash Interest Paid on Term Loan From Restricted Cash Cash income taxes paid (refund) Income Taxes Paid (Refund) Income Taxes Paid (Refund) Reclass of common stock warrant liability to additional paid-in capital upon warrant exercise Reclass of Common Stock Warrant Liability To Additional Paid In Capital Upon Exercise Value of reclass of common stock warrant liability to additional paid-in capital upon exercise in noncash financing activities. Fair value of warrant, at issuance date, in connection with loan agreement and recorded as warrant liability Liabilities Assumed Stock options activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Stock appreciation rights award activity Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block] Restricted stock and restricted stock units activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Debt Disclosure [Abstract] US Treasury Rate US Treasury Rate [Member] US Treasury Rate [Member] Effective interest rate (as a percent) Debt Instrument, Interest Rate During Period Interest expense, debt Interest Expense, Debt Interest paid on term loan Interest Paid Minimum cash requirement Line of Credit Facility, Minimum Cash Requirement Line of Credit Facility, Minimum Cash Requirement Potential increase in interest rate Line of Credit Facility, Debt Default, Increase in Interest Rate Line of Credit Facility, Debt Default, Increase in Interest Rate Costs incurred Debt Issuance Cost Fees and expenses Debt Instrument, Fee Amount Liabilities subject to compromise Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block] Accounts payable - pre-petition Liabilities subject to compromise, accounts payable The amount of pre-petition trade accounts payable included in liabilities subject to compromise. Accrual- PharmAthene Litigation Loss Contingency Accrual Other accrued expenses - pre-petition Liabilities subject to compromise, other accrued expense The amount of pre-petition accrued expense included in liabilities subject to compromise. Liabilities subject to compromise Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive employee share-based awards, excluded Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Stock Compensation Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Statutory federal income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent State tax benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Gain (loss) from fair value of common warrants Effective Income Tax Rate Reconciliation Loss From Fair Value of Common Warrants The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to changes in the fair value of common warrants. Reorganization costs Effective Income Tax Rate Reconciliation Loss From Reorganization Costs The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to changes in reorganization costs. Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Valuation allowance on deferred tax assets Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effective tax rate Effective Income Tax Rate Reconciliation, Percent Value of contract Government Contract, Value of Award 1 Value of base contract award. Contract value of manufacturing and delivery activities Contract Value of Manufacturing and Delivery Activities Contract value of manufacturing and delivery activities. Number of courses under modified contract Government Contract, Number of Courses Purchased Under Modified Contract Government contract, number of courses to be purchased under modified contract. Contract value of development and support activities Contract Value of Development and Support Activities Contract value of development and support activities Government contract, number of free courses Government Contract, Number of Free Courses Number of courses of tecovirimat to be contributed to the Strategic Stockpile at no cost to the government. Increase in payments for delivery of courses of TPOXX Increase in payments for delivery of courses of TPOXX Increase in payments for delivery of courses of TPOXX Holdback amount pending FDA approval Holdback amount pending FDA approval Holdback amount pending FDA approval Milestone payment Milestone payment Proceeds from milestone payment, Government contracts Proceeds from advance payments under the BARDA contract Proceeds from Advance Payments, Government Contracts Proceeds from advance payments, government contracts Proceeds from physical delivery of courses, government contracts Proceeds From Physical Delivery Of Courses, Government Contracts Proceeds from physical delivery of courses, government contract. Future proceeds to be received from BARDA Future proceeds to be received from BARDA Future proceeds to be received from BARDA Future proceeds to be received from the future deliveries of courses to the government Future proceeds to be received from the future deliveries of courses to the government Future proceeds to be received from the future deliveries of courses to the government Number of courses of TPOXX to be delivered to the government Number of Courses to be Delivered by Company Number of Courses to be Delivered by Company Number of courses delivered and accepted at provisional dosage, once daily Number Of Courses Delivered And Accepted At Provisional Dosage, Once Daily Number of tecovirimat, also known as ST-246, courses delivered and accepted at the provisional dosage of 600 mg once daily to the U.S. Strategic National Stockpile. Contract value of various options Contract Value of Various Options Contract value of various options exercisable at BARDA's discretion. Amount of option to be received from BARDA for approval for extension of 84 moth expiry Amount of option to be received from BARDA for approval for extension of 84 moth expiry Amount of option to be received from BARDA for approval for extension of 84 moth expiry Contract value, detail of option exercisable, development activities Contract Value, Detail Of Option Exercisable, Development Activities Contract value of option exercisable, amount represents exercisable option that would fund development and support activities, at BARDA's discretion. Contract value, detail of option exercisable, production activities Contract Value, Detail Of Option Exercisable, Production Activities Contract value of option exercisable, amount represents exercisable option that would fund production activities, at BARDA's discretion. Contract value, option, FDA approval Contract Value, Option, FDA Approval Contract value of option exercisable, FDA approval for extension to 84-month expiry for Tecovirimat, at BARDA's discretion. Deferred revenue Deferred Revenue Research and development revenue long-term contract Research and Development Revenue Long-term Contract Revenue earned during the period arising from research and development services provided under the terms of a long-term contract. May include government contracts and any other contract related to a particular project or product. Number of active contracts Number of Active Contracts Number of active contracts. Number of active grants Number of Active Grants Number of active grants Debt Debt Disclosure [Text Block] Schedule of Restricted Cash and Cash Equivalents [Table] Schedule of Restricted Cash and Cash Equivalents [Table] Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Total stockholders' equity (in shares) Total stockholders' equity Issuance of common stock upon exercise of RSU's, shares Stock Issued During Period, Shares, Conversion of Units Issuance of common stock upon exercise of RSU's, value Stock Issued During Period, Value, Conversion of Units Issuance of common stock upon exercise of stock options and warrants (in shares) Issuance of common stock upon exercise of stock options and warrants Proceeds from Stock Options Exercised Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Change in excess tax benefit stock-based compensation, value Payment of common stock tendered for employee stock-based compensation tax obligations (in shares) Shares Paid for Tax Withholding for Share Based Compensation Payment of common stock tendered for employee stock-based compensation tax obligations Issuance of common stock associated with rights offering, value Stock Issued During Period, Value, Rights Offering Stock Issued During Period, Value, Rights Offering Issuance of common stock associated with backstop agreement, shares Stock Issued During Period, Shares, Backstop Agreement Stock Issued During Period, Shares, Backstop Agreement Issuance of common stock associated with backstop agreement, value Stock Issued During Period, Value, Backstop Agreement Stock Issued During Period, Value, Backstop Agreement Total stockholders' equity (in shares) Total stockholders' equity Legal and expert fees accrual - PharmAthene Litigation Liabilities subject to compromise, loss contingency legal fees The amount of pre-petition loss contingency liability representing legal and expert fees accrued and included in liabilities subject to compromise. Surety bond Surety bond Amount of surety bond. Payment to post collateral for surety bond Payment to Post Collateral for Surety Bond Payment to post collateral for surety bond. Expense directly attributable to the implementation of the plan Liabilities Subject to Compromise, Expense (Income) Items Reorganization payments Reorganization Payments The amount the Company paid for reorganization items.